TY - JOUR T1 - Risk of myocarditis following sequential COVID-19 vaccinations by age and sex JF - medRxiv DO - 10.1101/2021.12.23.21268276 SP - 2021.12.23.21268276 AU - Martina Patone AU - Xue W Mei AU - Lahiru Handunnetthi AU - Sharon Dixon AU - Francesco Zaccardi AU - Manu Shankar-Hari AU - Peter Watkinson AU - Kamlesh Khunti AU - Anthony Harnden AU - Carol AC Coupland AU - Keith M. Channon AU - Nicholas L Mills AU - Aziz Sheikh AU - Julia Hippisley-Cox Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/12/25/2021.12.23.21268276.abstract N2 - In an updated self-controlled case series analysis of 42,200,614 people aged 13 years or more, we evaluate the association between COVID-19 vaccination and myocarditis, stratified by age and sex, including 10,978,507 people receiving a third vaccine dose. Myocarditis risk was increased during 1-28 days following a third dose of BNT162b2 (IRR 2.02, 95%CI 1.40, 2.91). Associations were strongest in males younger than 40 years for all vaccine types with an additional 3 (95%CI 1, 5) and 12 (95% CI 1,17) events per million estimated in the 1-28 days following a first dose of BNT162b2 and mRNA-1273, respectively; 14 (95%CI 8, 17), 12 (95%CI 1, 7) and 101 (95%CI 95, 104) additional events following a second dose of ChAdOx1, BNT162b2 and mRNA-1273, respectively; and 13 (95%CI 7, 15) additional events following a third dose of BNT162b2, compared with 7 (95%CI 2, 11) additional events following COVID-19 infection. An association between COVID-19 infection and myocarditis was observed in all ages for both sexes but was substantially higher in those older than 40 years. These findings have important implications for public health and vaccination policy.Funding Health Data Research UK.Competing Interest StatementAS is a member of the Scottish Government Chief Medical Officer's COVID-19 Advisory Group, the Scottish Government's Standing Committee on Pandemics. and AstraZeneca's Thrombotic Thrombocytopenic Advisory Group. All roles are unremunerated. JHC reports grants from National Institute for Health Research (NIHR) Biomedical Research Centre, Oxford, grants from John Fell Oxford University Press Research Fund, grants from Cancer Research UK (CR-UK) grant number C5255/A18085, through the Cancer Research UK Oxford Centre, grants from the Oxford Wellcome Institutional Strategic Support Fund (204826/Z/16/Z) and other research councils, during the conduct of the study. JHC is an unpaid director of QResearch, a not-for-profit organisation which is a partnership between the University of Oxford and EMIS Health who supply the QResearch database used for this work. JHC is a founder and shareholder of ClinRisk ltd and was its medical director until 31st May 2019. ClinRisk Ltd produces open and closed source software to implement clinical risk algorithms (outside this work) into clinical computer systems. JHC is chair of the NERVTAG risk stratification subgroup and a member of SAGE COVID-19 groups and the NHS group advising on prioritisation of use of monoclonal antibodies in SARS-CoV-2 infection. AH is a member of the Joint Committee on Vaccination and Immunisation (JCVI). KK is a member of the Governments Scientific Advisory Group for Emergencies. All other authors declare no competing interests related to this paper.Clinical Protocols https://www.qresearch.org/media/1304/ox107_covid_vaccine_safety_protocol.pdf Funding StatementFunding: Health Data Research UK.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:National Health Service Research Ethics Committee (NHS REC) approval was obtained from East Midlands-Derby Research Ethics Committee [reference 04/03/2021].I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study - National Immunisation (NIMS) Database of COVID-19, mortality (ONS), hospital admissions (HES) and SARS-CoV-2 infection data (PHE) -are not publicly available because they are based on de-identified national clinical records. Due to national and organizational data privacy regulations, individual-level data such as those used for this study cannot be shared openly. ER -